rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains

Beckert P, Hillemann D, Kohl T, Kalinowski J, Richter E, Niemann S, Feuerriegel S (2012)
Antimicrobial Agents and Chemotherapy 56(5): 2743-2745.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ;
Abstract / Bemerkung
The ribosomal L3 protein was identified as a novel target in linezolid (LZD)-resistant Mycobacterium tuberculosis strains. Next-generation sequencing confirmed rplC T460C as the sole mutation in an LZD-resistant M. tuberculosis H37Rv strain selected in vitro. Sequencing analysis revealed the rplC T460C mutation in eight further LZD-resistant isolates (three in vitro-selected mutants and five patient isolates, including isolates from three different patients that developed LZD resistance during treatment) but in none of the susceptible control strains (n = 84).
Erscheinungsjahr
Zeitschriftentitel
Antimicrobial Agents and Chemotherapy
Band
56
Zeitschriftennummer
5
Seite
2743-2745
ISSN
eISSN
PUB-ID

Zitieren

Beckert P, Hillemann D, Kohl T, et al. rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy. 2012;56(5):2743-2745.
Beckert, P., Hillemann, D., Kohl, T., Kalinowski, J., Richter, E., Niemann, S., & Feuerriegel, S. (2012). rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy, 56(5), 2743-2745. doi:10.1128/AAC.06227-11
Beckert, P., Hillemann, D., Kohl, T., Kalinowski, J., Richter, E., Niemann, S., and Feuerriegel, S. (2012). rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy 56, 2743-2745.
Beckert, P., et al., 2012. rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy, 56(5), p 2743-2745.
P. Beckert, et al., “rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains”, Antimicrobial Agents and Chemotherapy, vol. 56, 2012, pp. 2743-2745.
Beckert, P., Hillemann, D., Kohl, T., Kalinowski, J., Richter, E., Niemann, S., Feuerriegel, S.: rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy. 56, 2743-2745 (2012).
Beckert, Patrick, Hillemann, Doris, Kohl, Thomas, Kalinowski, Jörn, Richter, Elvira, Niemann, Stefan, and Feuerriegel, Silke. “rplC T460C Identified as a Dominant Mutation in Linezolid-Resistant Mycobacterium tuberculosis Strains”. Antimicrobial Agents and Chemotherapy 56.5 (2012): 2743-2745.

21 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T., J Genet Genomics 44(1), 2017
PMID: 28117224
Linezolid: a promising option in the treatment of Gram-positives.
Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H., J Antimicrob Chemother 72(2), 2017
PMID: 27999068
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM., Lancet Respir Med (), 2017
PMID: 28344011
Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.
Gygli SM, Borrell S, Trauner A, Gagneux S., FEMS Microbiol Rev 41(3), 2017
PMID: 28369307
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
Zimenkov DV, Nosova EY, Kulagina EV, Antonova OV, Arslanbaeva LR, Isakova AI, Krylova LY, Peretokina IV, Makarova MV, Safonova SG, Borisov SE, Gryadunov DA., J Antimicrob Chemother 72(7), 2017
PMID: 28387862
Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis.
Brossier F, Sougakoff W, French National Reference Center for Mycobacteria(b)., Med Mal Infect 47(5), 2017
PMID: 28629614
The Complete Structure of the Mycobacterium smegmatis 70S Ribosome.
Hentschel J, Burnside C, Mignot I, Leibundgut M, Boehringer D, Ban N., Cell Rep 20(1), 2017
PMID: 28683309
In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.
McNeil MB, Dennison DD, Shelton CD, Parish T., Antimicrob Agents Chemother 61(10), 2017
PMID: 28760892
Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.
Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, Chan D, Yew WW, Zhang W, Zhang Y., Antimicrob Agents Chemother 60(4), 2016
PMID: 26810645
Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.
Makafe GG, Cao Y, Tan Y, Julius M, Liu Z, Wang C, Njire MM, Cai X, Liu T, Wang B, Pang W, Tan S, Zhang B, Yew WW, Lamichhane G, Guo J, Zhang T., Antimicrob Agents Chemother 60(5), 2016
PMID: 26953211
Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
Wasserman S, Meintjes G, Maartens G., Expert Rev Anti Infect Ther 14(10), 2016
PMID: 27532292
Bioinformatics tools and databases for whole genome sequence analysis of Mycobacterium tuberculosis.
Faksri K, Tan JH, Chaiprasert A, Teo YY, Ong RT., Infect Genet Evol 45(), 2016
PMID: 27637931
Mutations in the bacterial ribosomal protein l3 and their association with antibiotic resistance.
Klitgaard RN, Ntokou E, Nørgaard K, Biltoft D, Hansen LH, Trædholm NM, Kongsted J, Vester B., Antimicrob Agents Chemother 59(6), 2015
PMID: 25845869
Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.
Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK., Antimicrob Agents Chemother 58(1), 2014
PMID: 24189255
In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, Marriner G, Balasubramanian V, Cole ST., Antimicrob Agents Chemother 58(6), 2014
PMID: 24663022
Drug Resistance Mechanisms in Mycobacterium tuberculosis.
Palomino JC, Martin A., Antibiotics (Basel) 3(3), 2014
PMID: 27025748
From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition.
Perdigão J, Macedo R, Silva C, Machado D, Couto I, Viveiros M, Jordao L, Portugal I., J Antimicrob Chemother 68(1), 2013
PMID: 23054995
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.
Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE., N Engl J Med 367(16), 2012
PMID: 23075177

13 References

Daten bereitgestellt von Europe PubMed Central.

Oxazolidinones: activity, mode of action, and mechanism of resistance.
Bozdogan B, Appelbaum PC., Int. J. Antimicrob. Agents 23(2), 2004
PMID: 15013035
In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.
Hillemann D, Rusch-Gerdes S, Richter E., Antimicrob. Agents Chemother. 52(2), 2008
PMID: 18070973
Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A, Mondal R., FEMS Immunol. Med. Microbiol. 53(2), 2008
PMID: 18479439
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.
Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS., Mol. Cell 26(3), 2007
PMID: 17499045
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.
Locke JB, Hilgers M, Shaw KJ., Antimicrob. Agents Chemother. 53(12), 2009
PMID: 19805557
Strategies against multidrug-resistant tuberculosis.
Loddenkemper R, Sagebiel D, Brendel A., Eur Respir J Suppl 36(), 2002
PMID: 12168749
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C; TBNET Study Group, Hurevich H, Skrahin A, Muetterlein R, Schaberg T, Eberhardt R, Flick H, de Roux A, Hamm M, Hang H, Hannemann P, Hillemann D, Kretz B, Laumanns C, Paulick A, Pletz MW, Rau M, Schaudt C, Matteelli A, Spanevello A, Toungoussova O, D'Ambrosio L, De Lorenzo S, Troupioti P, De Iaco G, Gualano A, De Mori P, Lauria FN, Ferrara G, Cirillo D, Janssens JP., Eur. Respir. J. 34(2), 2009
PMID: 19282348
Current and novel antibiotics against resistant Gram-positive bacteria.
Perez F, Salata RA, Bonomo RA., Infect Drug Resist 1(), 2008
PMID: 21694878
First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Richter E, Rusch-Gerdes S, Hillemann D., Antimicrob. Agents Chemother. 51(4), 2007
PMID: 17242139
Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S., Clin. Infect. Dis. 50(1), 2010
PMID: 19947856
Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus.
Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, Klugman KP., Antimicrob. Agents Chemother. 49(8), 2005
PMID: 16048983

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 22371899
PubMed | Europe PMC

Suchen in

Google Scholar